Longboard Pharmaceuticals Announces Positive Interim Results From 52-Week Open-Label Extension Of PACIFIC Study Evaluating Bexicaserin (LP352) In Participants With Developmental And Epileptic Encephalopathies
$LBPH
Biotechnology: Pharmaceutical Preparations
Health Care
- Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%
- Favorable safety and tolerability results observed
- 100% of participants who completed the PACIFIC Study entered the OLE
- End of Phase 2 Meeting scheduled for this summer